Project Grant R43HL186093
Award Date 8/15/26
Completion Date 8/14/27
Dollars Obligated $294K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10010, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Coridea, LLC $305,365 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cooled radiofrequency bronchoscopic lung volume reduction technology for severe emphysema patients. The project addresses a clinical gap in lung volume reduction therapy. Current surgical options reach only a fraction of severe emphysema patients: wedge excision LVR surgery is invasive and limits candidate eligibility, while...
- The National Heart, Lung, and Blood Institute awarded Corfigo, Inc. $447,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the HeartPad Cryoablation System, a device for treating atrial fibrillation by performing full-thickness ablation of cardiac tissue from the epicardial surface on a beating heart. The HeartPad leverages liquid helium cooling and high-efficiency heat exchangers to ablate contiguous epicardial adipose tissue and atrial muscle...
- The National Heart, Lung, and Blood Institute awarded $782,341 to the University of Pittsburgh on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate an adaptive, artificial intelligence-guided, closed-loop neuromodulation system for real-time prediction and prevention of ventricular arrhythmias in patients with prior myocardial infarction. The system will coordinate spinal cord stimulation and selective cardiac vagus nerve stimulation to...
- The National Heart, Lung, and Blood Institute awarded Vivamed, Inc. $257,015 on June 15, 2026, to develop a wirelessly powered, battery-free hypoglossal nerve stimulator for treating obstructive sleep apnea under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a minimally invasive implantable device designed to address limitations of existing hypoglossal nerve stimulation systems. The device will integrate electromyography sensors for real-time muscle...
- The National Heart, Lung, and Blood Institute awarded Autonomous Healthcare Inc. $305,999 on September 1, 2026, under the Small Business Innovation Research (SBIR) program to conduct a Phase I feasibility study of E-Fusion, a bedside clinical decision support system designed to assist anesthesiologists, anesthetists, and critical care nurses with vasopressor titration and blood pressure management during surgery and in the intensive care unit. The system monitors mean arterial pressure (MAP) and...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Sigt LLC $848,381 on September 1, 2026, to develop a clinical-grade intraoperative cardiac pulsed field ablation and lesion assessment system under the Cardiovascular Diseases Research program (CFDA 93.837), a Phase II Small Business Innovation Research project. Sigt LLC will develop a pulsed field ablation lesion assessment system (PFA-LAS) using proprietary high frequency dielectric sensing (HFDS) technology to enable intraoperative...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $1,657,587 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect molecular pathways controlling human pacemaker development. The recipient will conduct research aimed at identifying key transcriptional regulators of sinoatrial node (SAN) differentiation using CRISPR interference and activation in human pluripotent stem cells, then validate findings in...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded Corvion, Inc. $2,999,968 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel pediatric left ventricular assist device (P-LVAD) enabling children with end-stage heart failure to discharge home while awaiting heart transplantation or living long-term with the device. This is a Project Grant (SBIR Phase II). Corvion will engineer an implantable, ultra-low-power blood pump combining hydrodynamic...